ft 13 oct 94 technolog new era ms treatment look two drug may slow diseas multipl sclerosi patient hand small drug compani develop treatment diseas may enter new era suffer ms second common neurolog diseas among young adult week abl take heart result clinic trial two new drug reveal american neurolog associ meet san francisco result good enough make like 1996 sever ms drug market compar one today none cure condit appear slow sharpli diseas progress supplier result herald period tough competit market worth dollar 1 4bn pound 930m annual 1998 say stockbrok lehman brother battl revenu centr clinic trial result mesh patent area four main supplier germani schere sell betaseron israel teva copaxon switzerland are serono biogen us beta interferon past year betaseron approv treatment ms work interf immun system thought fault ms betaseron made genet engin bacteria quit ident beta interferon produc natur human bodi biogen are serono hand use genet engin mammal cell make beta interferon chemic ident human version principl mean drug work better human bodi perhap fewer side effect data publish week first larg scale trial beta interferon copaxon result biogen trial 301 ms suffer probabl clear compani would like direct comparison result earlier betaseron trial difficult drug compar directli placebo side effect flu like symptom seem fewer beta interferon could patient biogen trial also given paracetamol tylenol depress fever furthermor effect biogen drug gaug fast patient condit deterior slow progress diseas almost half betaseron test measur frequenc ms attack howev littl choos two drug us food drug administr regulatori bodi elsewher like examin close data biogen whose share fell trial result publish face tough question claim superior betaseron patent cover beta interferon also seem set fought cascad licens agreement start research institut japan california involv are serono sub licenc one patent biogen schere tri use beta interferon betaseron anoth diseas area hepat stand aloof teva isra compani whose copaxon appear work differ ill understood way achiev modestli encourag result cut number ms attack less achiev betaseron may safer betaseron beta interferon could market patient react badli two messag emerg san francisco principl interferon help ms suffer good life take drug may get littl easier howev drug compani face bruis battl win sale